AOD-9604 Self-Injection Technique: Step-by-Step Subcutaneous Administration Guide

What AOD-9604 is, and why it is injected rather than swallowed

AOD-9604 is a short synthetic peptide, about sixteen amino acids, modeled on the C-terminal fragment (positions 176 to 191) of human growth hormone, with an added tyrosine residue intended to improve stability. It is sometimes marketed under the name AOD9604. It should not be confused with full-length recombinant human growth hormone (somatropin), which is a much larger, FDA-approved molecule with a different receptor-binding profile.

Peptides of this size are broken down by digestive enzymes and hepatic first-pass metabolism if swallowed, which is why compounding prescribers dispense it as an injectable solution rather than an oral product. Subcutaneous injection avoids the gut and liver entirely and delivers the peptide directly into the fat layer beneath the skin.

AOD-9604 is not FDA-approved for weight loss, fat reduction, or any other indication as of this writing; regulatory status should be reconfirmed at the time of use. It is dispensed through section 503A compounding pharmacies under an individual prescription, governed by the FDA's compounding laws and policies. Compounded preparations are not subject to the same premarket review as FDA-approved drugs, so batch-to-batch purity, concentration accuracy, and sterility depend entirely on the individual pharmacy's quality systems. Patients should confirm their pharmacy's state licensure and, where available, third-party accreditation such as PCAB.

The core, quotable fact: AOD-9604 is a compounded, non-FDA-approved peptide fragment of growth hormone that is injected subcutaneously because oral delivery would destroy it; rodent studies have reported fat-mobilizing activity without GH-receptor engagement, but no completed human injectable trial has established efficacy or long-term safety, so dosing, cycle length, and monitoring intervals described by compounding prescribers reflect clinical practice rather than validated protocol.

What the mechanism evidence actually supports

The rationale for AOD-9604 rests on preclinical work suggesting that the 176-191 fragment retains the lipid-mobilizing activity of full-length growth hormone without binding the classical GH receptor, and therefore without raising IGF-1 or provoking the insulin resistance associated with high-dose GH therapy. Reported rodent studies describe reduced fat mass in obese mice given the fragment, with stable blood glucose and IGF-1, and a blunted response in mice lacking beta-3 adrenergic receptors, pointing to that receptor pathway as a likely effector mechanism. A separate report describes a Phase IIb oral-formulation trial in obese adults that did not meet its primary weight-loss endpoint, an outcome the trial authors attributed partly to poor oral bioavailability rather than lack of biological activity.

These findings come from the peptide-development literature associated with AOD-9604's originators, and the specific identifiers attached to them in prior drafts of this material could not be verified against the primary papers during this review. Editors and reviewers should confirm the exact citations, sample sizes, and effect sizes against the original journal articles before publication rather than relying on secondhand summaries. Until that verification happens, treat the fat-reduction magnitude, the specific mouse strain protocol details, and the "no change in glucose or IGF-1" claim as plausible but unconfirmed for this draft.

What is established: the peptide's chemical structure and molecular weight, and the general pharmacologic principle that peptides of this size are degraded by oral administration.

What is plausible but not established in humans: that the fragment produces clinically meaningful fat loss without the metabolic risks of full-length GH. The supporting data are rodent and small early-phase studies, not confirmatory human trials.

What is not established: an effective and safe human dose, an optimal treatment duration, and long-term safety with repeated dosing cycles.

Supplies for self-injection

• AOD-9604 vial as dispensed by your pharmacy (lyophilized powder)
• Bacteriostatic water for injection (USP), the diluent generally used for multi-dose peptide vials because its preservative limits microbial growth between draws
• Insulin-type syringes with a fine, fixed needle, sized as instructed by the dispensing pharmacy
• Alcohol swabs (70% isopropyl alcohol)
• An FDA-cleared sharps container
• A clean, flat surface

General public health guidance on safe injection practices, written primarily for healthcare settings, applies its core rules to any injectable medication handled at home: use a new sterile syringe and needle for every injection, never recap a used needle by hand, never share a vial or syringe between people, and dispose of sharps immediately into a puncture-resistant container. These are baseline safety practices, not optional extras, regardless of what is being injected.

Sterile water without a preservative is intended for single-dose use and should not be used to reconstitute a vial that will be drawn from repeatedly over days or weeks, because it lacks the antimicrobial protection that bacteriostatic water provides across a multi-dose use window. Regulatory advisories generally underscore the risk of contamination when injectable products are handled or reused improperly outside a controlled clinical setting.

Reconstituting the vial

1. Bring the AOD-9604 vial and the bacteriostatic water to room temperature for a few minutes; do not warm them artificially.
2. Wipe both rubber stoppers with a fresh alcohol swab and let them air-dry.
3. Draw the volume of bacteriostatic water specified by your pharmacy's instructions. The exact volume determines the resulting concentration, so follow your pharmacy's label rather than a generic ratio, since vial strengths vary by pharmacy.
4. Insert the needle into the peptide vial at an angle, letting the water run gently down the interior glass wall rather than spraying it directly onto the powder.
5. Swirl the vial gently in a circular motion until the powder fully dissolves. Do not shake or vortex; vigorous agitation can shear peptide bonds and reduce potency.
6. The solution should be clear and colorless. Discard the vial if you see cloudiness, discoloration, or particulate matter, and contact your pharmacy for a replacement.
7. Label the vial with the reconstitution date, and refrigerate it promptly.

Beyond-use dating for compounded sterile peptide preparations is governed by USP sterile compounding standards, and the specific number of days a given vial remains usable depends on the compounding pharmacy's own testing and labeling, not a single universal figure. Follow the beyond-use date printed on your pharmacy's label rather than a general rule found online.

Step-by-step subcutaneous injection

The mechanics below follow general subcutaneous injection technique of the kind used for insulin and other self-injected medications. They describe a widely taught technique, not a peptide-specific validated protocol; peptide-specific comparative studies of injection angle, speed, or site have not been established for AOD-9604.

Before injecting

1. Wash hands with soap and water for at least twenty seconds.
2. Wipe the vial stopper with alcohol and let it dry.
3. Invert the vial gently two or three times; do not shake.
4. Draw the prescribed dose into a new syringe, matching the markings on the syringe to the dose your prescriber specified for your vial's concentration.
5. Point the syringe upward, tap out any air bubbles, and expel a small amount of air before injecting.

Choosing and rotating the site

Common subcutaneous sites include the periumbilical abdomen (roughly two inches from the navel, avoiding the midline and visible veins), the outer middle third of the anterior thigh, and, for caregiver-administered injections, the posterior upper arm. Repeated injection into the same small area of skin can cause lipohypertrophy, a localized thickening of fat under the skin that impairs absorption; this is a recognized complication of repeated subcutaneous injection generally, not something specific to AOD-9604. Rotating between at least two sites, for example alternating left abdomen, right abdomen, left thigh, and right thigh, reduces this risk.

Giving the injection

1. Clean the site with alcohol and let it air-dry fully; injecting through wet alcohol stings.
2. Pinch a fold of skin between thumb and forefinger.
3. Insert the needle into the pinched fold at an angle appropriate to the needle length and your body composition, following your prescriber's specific instruction rather than a fixed universal angle.
4. Depress the plunger slowly and steadily.
5. Hold the needle in place briefly after the plunger is fully depressed before withdrawing, to reduce medication tracking back along the needle path.
6. Release the pinch and withdraw the needle at the same angle used for insertion.
7. Apply light pressure with gauze if a small amount of blood appears; do not rub the site.
8. Dispose of the syringe immediately in the sharps container.

Dosing and timing: what is prescriber judgment versus what is proven

Compounding prescribers commonly recommend once-daily subcutaneous dosing, sometimes split into two smaller doses if a patient has not responded after several weeks. This is a matter of individual prescriber and pharmacy practice, not a dose validated in controlled human trials, and no published injectable human trial defines an evidence-based optimal dose, frequency, or treatment duration for AOD-9604. Any specific number quoted online, including in earlier versions of guidance like this, should be treated as a starting point for a conversation with your own prescriber rather than a fixed instruction.

Some prescribers suggest administering on an empty stomach on the reasoning that postprandial insulin release could blunt lipolytic signaling; this is a plausible pharmacologic hypothesis extrapolated from general endocrinology, not a finding demonstrated for AOD-9604 specifically in humans.

Treatment courses of roughly three to four months, sometimes followed by a rest period, and periodic laboratory monitoring of fasting glucose, IGF-1, and lipids are reported as common clinical practice among prescribers of compounded peptides. No clinical trial data define an optimal cycle length or monitoring interval for AOD-9604 specifically; these intervals reflect general caution around an unapproved therapy rather than a proven protocol. This is individualized medical decision-making that belongs with your prescriber, not a instruction to follow independently.

Storage and stability

Store unopened lyophilized vials refrigerated as instructed by your pharmacy's label; peptides generally degrade faster with heat and light exposure through hydrolysis and oxidation. After reconstitution, keep the vial refrigerated, protected from light, and use it within the beyond-use window specified on your pharmacy's label. Never freeze a reconstituted peptide solution, since ice crystal formation can mechanically damage the peptide structure. Do not leave a reconstituted vial at room temperature for extended periods, and inspect the solution before every use, discarding it if it looks cloudy, discolored, or contains particles.

Safety, side effects, and when to contact your prescriber

Mild injection-site redness, slight swelling, or brief stinging are common with subcutaneous injections generally and typically resolve within a short time. Because AOD-9604 has no completed Phase III human injectable trials, there is no large formal dataset describing its systemic side-effect profile; reported observations from smaller studies and clinical experience suggest infrequent systemic effects at commonly used doses, but this has not been established with the rigor applied to an FDA-approved drug.

Contact your prescriber promptly if you notice:

• Signs of infection at the injection site: spreading redness, warmth, pus, or fever
• A persistent headache lasting more than a day
• Unexpected changes in blood glucose, particularly if you have diabetes or prediabetes
• Signs of an allergic reaction: hives, facial or throat swelling, or difficulty breathing

The last of these, difficulty breathing or facial swelling, is a reason to seek urgent or emergency care rather than waiting to reach your prescriber.

Because compounded products are not subject to the same manufacturing oversight as FDA-approved drugs, product quality varies by pharmacy. Confirming your pharmacy's licensure and accreditation status, as described above, is a reasonable step before starting treatment.

AOD-9604 versus full-length growth hormone

Patients sometimes assume AOD-9604 will produce growth-hormone-like effects on muscle or bone. The available evidence does not support that expectation; its proposed activity is limited to fat metabolism, and even that has not been confirmed in a completed human injectable trial.

Self-injection troubleshooting and stop-decision framework

This is a practical decision aid for people already prescribed AOD-9604 by a licensed provider. It does not replace instructions from your prescriber or pharmacy.

The through-line of this framework: local skin reactions and vial-handling problems are usually manageable by good technique and site rotation, but anything suggesting infection, allergic reaction, or unexplained metabolic change should go to a prescriber promptly rather than being managed by adjusting the injection routine alone, given how limited the confirmed human safety data are for this compound.